178 related articles for article (PubMed ID: 31959340)
1. Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.
Barbour AP; Walpole ET; Mai GT; Barnes EH; Watson DI; Ackland SP; Martin JM; Burge M; Finch R; Karapetis CS; Shannon J; Nott LM; Varma S; Marx G; Falk GL; Gebski V; Oostendorp M; Wilson K; Thomas J; Lampe G; Zalcberg JR; Simes J; Smithers BM;
Ann Oncol; 2020 Feb; 31(2):236-245. PubMed ID: 31959340
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma.
Mercieca-Bebber R; Barnes EH; Wilson K; Samoon Z; Walpole E; Mai T; Ackland S; Burge M; Dickie G; Watson D; Leung J; Wang T; Bohmer R; Cameron D; Simes J; Gebski V; Smithers M; Thomas J; Zalcberg J; Barbour AP
BMC Cancer; 2022 Mar; 22(1):276. PubMed ID: 35291965
[TBL] [Abstract][Full Text] [Related]
3. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
4. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer.
Yokota T; Kato K; Hamamoto Y; Tsubosa Y; Ogawa H; Ito Y; Hara H; Ura T; Kojima T; Chin K; Hironaka S; Kii T; Kojima Y; Akutsu Y; Matsushita H; Kawakami K; Mori K; Nagai Y; Asami C; Kitagawa Y
Br J Cancer; 2016 Nov; 115(11):1328-1334. PubMed ID: 27811857
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
Alderson D; Cunningham D; Nankivell M; Blazeby JM; Griffin SM; Crellin A; Grabsch HI; Langer R; Pritchard S; Okines A; Krysztopik R; Coxon F; Thompson J; Falk S; Robb C; Stenning S; Langley RE
Lancet Oncol; 2017 Sep; 18(9):1249-1260. PubMed ID: 28784312
[TBL] [Abstract][Full Text] [Related]
7. Five-year Outcomes of Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Oesophagectomy in Oesophageal Cancer.
Tanishima Y; Nishikawa K; Arakawa Y; Matsumoto A; Yuda M; Tanaka Y; Mitsumori N; Yanaga K
Anticancer Res; 2020 Oct; 40(10):5829-5835. PubMed ID: 32988912
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
Starling N; Okines A; Cunningham D; Allum W; Wotherspoon A; Benson M; Thompson J; Thomas J; Brown G; Riddell A; Stavridi F; Ashley S; Oates J; Chau I
Br J Cancer; 2009 Jun; 100(11):1725-30. PubMed ID: 19436301
[TBL] [Abstract][Full Text] [Related]
10. Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus.
Ui T; Fujii H; Hosoya Y; Nagase M; Mieno MN; Mori M; Zuiki T; Saito S; Kurashina K; Haruta H; Matsumoto S; Niki T; Lefor A; Yasuda Y
Dis Esophagus; 2015; 28(2):180-7. PubMed ID: 24529073
[TBL] [Abstract][Full Text] [Related]
11. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
[TBL] [Abstract][Full Text] [Related]
12. Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan.
Matsuda S; Kitagawa Y; Takemura R; Okui J; Okamura A; Kawakubo H; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
Ann Surg; 2023 Jul; 278(1):e35-e42. PubMed ID: 35837977
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
Yamagata Y; Saito K; Hirano K; Oya M
World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
[TBL] [Abstract][Full Text] [Related]
15. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
[TBL] [Abstract][Full Text] [Related]
16. Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
Kim S; Paget-Bailly S; Messager M; Nguyen T; Mathieu P; Lamfichekh N; Fein F; Fratté S; Cléau D; Lakkis Z; Jary M; Sakek N; Jacquin M; Foubert A; Bonnetain F; Mariette C; Fiteni F; Borg C
Eur J Surg Oncol; 2017 Jan; 43(1):218-225. PubMed ID: 27425578
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
18. Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Abgral R; Le Roux PY; Keromnes N; Rousset J; Valette G; Gouders D; Leleu C; Mollon D; Nowak E; Querellou S; Salaün PY
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1839-47. PubMed ID: 22895863
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma.
Fiteni F; Paget-Bailly S; Messager M; N'Guyen T; Lakkis Z; Mathieu P; Lamfichekh N; Picard A; Benzidane B; Cléau D; Bonnetain F; Borg C; Mariette C; Kim S
Cancer Med; 2016 Nov; 5(11):3085-3093. PubMed ID: 27726290
[TBL] [Abstract][Full Text] [Related]
20. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
